125 related articles for article (PubMed ID: 29684339)
21. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
[TBL] [Abstract][Full Text] [Related]
22. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
[TBL] [Abstract][Full Text] [Related]
23. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network.
Leathers JS; Balderramo D; Prieto J; Diehl F; Gonzalez-Ballerga E; Ferreiro MR; Carrera E; Barreyro F; Diaz-Ferrer J; Singh D; Mattos AZ; Carrilho F; Debes JD
J Clin Gastroenterol; 2019 Jul; 53(6):464-469. PubMed ID: 29952857
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection.
Bertacco A; Vitale A; Mescoli C; Cillo U
Per Med; 2020 Mar; 17(2):83-87. PubMed ID: 32157952
[TBL] [Abstract][Full Text] [Related]
26. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
27. Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel.
Bhardwaj S; Varma S
J Oncol Pharm Pract; 2018 Mar; 24(2):153-155. PubMed ID: 29284359
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
29. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
30. Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
Kim JO; Jun DW; Tae HJ; Lee KN; Lee HL; Lee OY; Choi HS; Yoon BC; Hahm JS
Clin Mol Hepatol; 2015 Mar; 21(1):85-8. PubMed ID: 25834806
[TBL] [Abstract][Full Text] [Related]
31. Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients.
Saito K; Ikeda M; Kojima Y; Hosoi H; Saito Y; Kondo S
Cancer Chemother Pharmacol; 2018 Oct; 82(4):677-684. PubMed ID: 30062555
[TBL] [Abstract][Full Text] [Related]
32. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
33. Tumor Lysis Syndrome after Combination Therapy of Nivolumab and Sorafenib in a Woman with Advanced Hepatocellular Carcinoma.
Yen TH; Chang CH; Shiu SI
Case Rep Gastroenterol; 2020; 14(2):367-372. PubMed ID: 32884512
[TBL] [Abstract][Full Text] [Related]
34. Tumor lysis syndrome in a nonsmall cell lung cancer.
Noyes AM; Lonial K; Siegel RD
Conn Med; 2014 Aug; 78(7):421-3. PubMed ID: 25195308
[TBL] [Abstract][Full Text] [Related]
35. Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma.
Wu CX; Wang XQ; Chok SH; Man K; Tsang SHY; Chan ACY; Ma KW; Xia W; Cheung TT
Theranostics; 2018; 8(14):3737-3750. PubMed ID: 30083256
[No Abstract] [Full Text] [Related]
36. Acute tumor lysis syndrome caused by transcatheter oily chemoembolization in a patient with a large hepatocellular carcinoma.
Sakamoto N; Monzawa S; Nagano H; Nishizaki H; Arai Y; Sugimura K
Cardiovasc Intervent Radiol; 2007; 30(3):508-11. PubMed ID: 17242878
[TBL] [Abstract][Full Text] [Related]
37. Acute tumor lysis syndrome after transarterial chemoembolization for well-differentiated hepatocellular carcinoma with neuroendocrine features.
Wang K; Chen Z
Onkologie; 2010; 33(10):532-5. PubMed ID: 20926901
[TBL] [Abstract][Full Text] [Related]
38. Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia.
Okay M; Çetik S; Haznedaroğlu İC
Turk J Haematol; 2019 Aug; 36(3):218-219. PubMed ID: 31067853
[No Abstract] [Full Text] [Related]
39. Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients.
Ruanglertboon W; Sorich MJ; Rowland A; Hopkins AM
Int J Clin Oncol; 2020 Sep; 25(9):1672-1677. PubMed ID: 32417993
[TBL] [Abstract][Full Text] [Related]
40. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma.
Lee CC; Wu YH; Chung SH; Chen WJ
Oncologist; 2006 Jan; 11(1):87-8; author reply 89. PubMed ID: 16401719
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
